Nanoparticles for Pulmonary Drug Delivery System: A Review of Recent Development

Authors

  • Jaimin P. Panchal
  • Sanjesh Rathi
  • Shubham Singh

Keywords:

Nanoparticles; SLN; toxicity; Lung Cell Models; Aerosol; Nebulization; Lung Disease

Abstract


In recent years, the development of nanoparticles for pulmonary drug delivery has gained significant attention due to their potential in enhancing the efficacy and safety of therapeutic interventions. The unique properties of nanoparticles allow for targeted delivery, controlled release, and improved drug bioavailability within the lungs. This review article provides an overview of recent advancements in the field of nanoparticles-based pulmonary drug delivery systems. We discuss various types of nanoparticles, their preparation methods, physicochemical characteristics, and the impact of these parameters on drug delivery efficiency. Furthermore, we explore the challenges and opportunities associated with the translation of nanoparticle-based pulmonary drug delivery systems from bench to bedside. Overall, this review highlights the promising potential of nanoparticles for improving pulmonary drug delivery and underscores the need for further research and development in this field

Downloads

Download data is not yet available.

References

Azarmi, S.; Roa, W.H.; Löbenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 2008, 60, 863–875.

2. Jaafar-Maalej, C.; Elaissari, A.; Fessi, H. Lipid-based carriers: Manufacturing and applications for pulmonary route. Expert Opin. Drug Deliv. 2012, 9, 1111–1127.

3. Nassimi, M.; Schleh, C.; Lauenstein, H.-D.; Hussein, R.; Lübbers, K.; Pohlmann, G.; Switalla, S.; Sewald, K.; Müller, M.; Krug, N.; et al. Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhal. Toxicol. 2009, 21, 104–109.

4. Nassimi, M.; Schleh, C.; Lauenstein, H.; Hussein, R.; Hoymann, H.; Koch, W.; Pohlmann, G. Krug, N.; Sewald, K.; Rittinghausen, S.; et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 2010, 75, 107–116.

5. Singh S, Singh S, Saw S, Rathi S, Sharma B. Single Cell Transcriptomics of Traditional Chinese Medicine Bioactives: Mapping Immune, Neural and Hepatic Responses. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2025 Nov 10;41:e20250028. doi: 10.62958/j.cjap.2025.028. PMID: 41207694.

6. Menon, J.U.; Ravikumar, P.; Pise, A.; Gyawali, D.; Hsia, C.C.W.; Nguyen, K.T. Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomater. 2014, in press, doi:10.1016/j.actbio.2014.01.033

7. Menon, J.U.; Wadajkar, A.S.; Xie, Z.; Nguyen, K.T. Nanomaterials for management of lung disorders and drug delivery. In Nanomaterials in Drug Delivery, Imaging, and Tissue Engineering; Tiwari, A., Tiwari, A., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2013; pp. 167–202.

8. Patel, P.; Soni, T.; Thakkar, V.; Gandhi, T. Nanoparticle as an emerging tool in pulmonary drug delivery system. MNS 2013, 5, 288–302.

9. Tena, A.F.; Clarà, P.C. Deposition of inhaled particles in the lungs. Arch Bronconeumol. 2012, 48, 240–246.

10. Yang, W.; Peters, J.I.; Williams, R.O. Inhaled nanoparticles—A current review. Int. J. Pharm.2008, 356, 239–247.

11. Patton, J.S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 1996, 19, 3–36.

12. Beck-Broichsitter, M.; Ruppert, C.; Schmehl, T.; Guenther, A.; Betz, T.; Bakowsky, U.; Seeger, W.; Kissel, T.; Gessler, T. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomed. Nanotechnology. Biol. Med. 2011, 7, 341–350.

13. Silva, L.F.C.; Kasten, G.; de Campos, C.E.M.; Chinelatto, A.L.; Lemos-Senna, E. Preparation and characterization of quercetin-loaded solid lipid microparticles for pulmonary delivery. Powder Technol. 2013, 239, 183–192.

14. Wang, W.; Zhu, R.; Xie, Q.; Li, A.; Xiao, Y.; Liu, H.; Wang, S.; Cui, D. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. IJN 2012, 7, 3667–3677.

15. Varshosaz, J.; Ghaffari, S.; Mirshojaei, S.F.; Jafarian, A.; Atyabi, F.; Kobarfard, F.; Azarmi, S. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed. Res. Int. 2013, 2013, 1–8.

16. DS Rajput, M Bhoi, S. Singh, Comment on Fennel essential oil and its nanoemulsion modulate macrophage-mediated inflammatory responses and promote pressure ulcer healing. International Immunopharmacology. 2026; 173:116184. https://doi.org/10.1016/j.intimp.2026.116184

17. Chiraz, J.-M.; Andrieu, V.; Elaissari, A.; Fessi, H. Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: Preparation, characterization and in vitro drug release. J. Nanosci. Nanotechnol. 2011, 11, 1841–1851.

18. Elhissi, A.; Islam, M.A.; Arafat, B.; Taylor, M.; Ahmed, W. Development and characterisation of freeze-dried liposomes containing two anti-asthma drugs. Micro Nano Lett. 2010, 5, 184.

19. Zhang, P.-R.; Xie, Y.; Li, M. Preparation and characterization of budesonide-loaded solid lipid nanoparticles for pulmonary delivery. J. Chin. Pharm. Sci. 2011, 20, 390–396.

20. Kumar, S.S.D.; Surianarayanan, M.; Vijayaraghavan, R.; Mandal, A.B.; MacFarlane, D.R. Curcumin loaded poly(2-hydroxyethyl methacrylate) nanoparticles from gelled ionic liquid—In vitro cytotoxicity and anti-cancer activity in SKOV-3 cells. Eur. J. Pharm. Sci. 2014, 51, 34–44.

21. Ali, R.; Mittal, G.; Ali, R.; Kumar, M.; Kishan Khar, R.; Ahmad, F.J.; Bhatnagar, A. Development, characterisation and pharmacoscintigraphic evaluation of nano-fluticasone propionate dry powder inhalation as potential antidote against inhaled toxic gases. J. Microencapsul. 2013, 30, 546–558.

22. Rao, A.K.; Shrikhande, S.; Bajaj, A. Development of cisplatin nanoparticles as dry powder inhalers for lung cancer. Curr. Nanosci. 2013, 9, 447–450.

23. Li, M. Methotrexate-conjugated and hyperbranched polyglycerol-grafted Fe3O4 magnetic nanoparticles for targeted anticancer effects. Eur. J. Pharm. Sci. 2013, 48, 111–120.

24. Gill, K.K.; Nazzal, S.; Kaddoumi, A. Paclitaxel loaded PEG5000–DSPE micelles as pulmonary delivery platform: Formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur. J. Pharm. Biopharm. 2011, 79, 276–284.

25. Chen, H.; Zhao, T.; Dong, Y.; Zhang, J.; Huang, H.; Zhu, J. Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy. IJN 2013, 8, 1947–1957.

Downloads

Published

2025-12-07

How to Cite

1.
P. Panchal J, Rathi S, Singh S. Nanoparticles for Pulmonary Drug Delivery System: A Review of Recent Development. J Neonatal Surg [Internet]. 2025 Dec. 7 [cited 2026 May 9];14(33S):981-9. Available from: https://jneonatalsurg.com/index.php/jns/article/view/10227

Issue

Vol. 14 No. 33S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.